Welcome to my minihompy! β¨
Loading Reality...
π Part of the OBX-319 Regulatory Dossier β Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing β the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Quality Management Plan (OBX319-301)
Why it exists. A quality record showing how the program controls quality and builds the audit trail.
How it is produced here. It is a quality record: a plan or log that shows how the program controls quality and builds the audit trail sitting behind every other document.
Format & governing standard. β
Document ID: QA-001
Version: 1.0
Change History: 1.0 β Initial issue.
Standard(s): ICH E6(R3)
Describes the quality system for OBX319-301: quality objectives, roles and responsibilities, risk-based quality management (critical-to-quality factors), deviation/CAPA handling, vendor oversight, and the audit/inspection-readiness approach. ICH E6(R3) quality management.
This Quality Management Plan (QMP) governs the design, conduct, oversight, and reporting of Study OBX319-301, a Phase 3, randomized, double-blind, placebo-controlled, 1:1:1, 52-week trial of OBX-319 on a background of standard-of-care in participants with moderate-to-severe active Systemic Lupus Erythematosus (SLE). OBX-319 is a humanized IgG1 anti-CD19 Γ anti-CD20 B-cell-depleting bispecific monoclonal antibody produced by Chinese hamster ovary (CHO) cell culture and administered subcutaneously. The QMP operationalizes the ICH E6(R3) principle that quality should be built into the scientific and operational design of the trial ("quality by design") and managed proportionately to the risks that matter to participant safety, rights, and well-being and to the reliability of results. The Sponsor, Virtual Biopharma Inc., holds ultimate accountability for the quality system described here; delegated activities remain under Sponsor oversight. This plan is a living document maintained under version control and reviewed at pre-specified milestones and whenever a material change in risk is identified.
No comments yet. Be the first to say something!
The overarching objective is that decision-critical data and processes are fit for purpose and that participant protection is never subordinated to operational convenience. Specific objectives are:
Progress against these objectives is monitored through pre-defined key risk indicators (KRIs) and quality tolerance limits (QTLs) and is reported to Sponsor governance on a recurring cadence.
Quality accountability is layered so that ownership is explicit at each level:
A RACI-style delegation log records who is responsible, accountable, consulted, and informed for each critical activity and is maintained alongside this plan.
A cross-functional risk assessment identifies the factors critical to quality, evaluates each for likelihood, impact, and detectability, and assigns proportionate mitigation, monitoring, and (where appropriate) QTLs. The assessment is revisited at defined intervals and upon triggering events. The CtQ factors specific to OBX319-301 are:
QTLs are defined for a limited set of parameters where a systematic departure would threaten the reliability of results or participant safety (for example, aggregate premature treatment discontinuation, primary-endpoint assessment completeness at Week 52, and IP temperature-excursion frequency). Breach of a QTL triggers a documented root-cause evaluation and, where warranted, corrective action, distinct from routine KRI drift, which prompts targeted follow-up.
Protocol deviations and quality events are captured, classified by impact (with important deviations flagged for aggregate review and inclusion in the clinical study report), and trended by site, region, and category. Root-cause analysis is applied proportionately to significance; corrective and preventive actions (CAPA) are assigned owners and due dates, verified for effectiveness, and closed with evidence. Recurrent or systemic issues β for example, repeated IP temperature excursions, missed PD/ADA sampling, or scoring inconsistencies on SLEDAI-2K β are escalated to Sponsor governance and, where relevant, feed back into the risk assessment and monitoring emphasis. The deviation/CAPA record is maintained in a controlled system and reconciled against the TMF.
Central vendors and investigative sites are qualified before engagement and overseen throughout the trial under written quality agreements that define roles, data ownership, quality expectations, and audit rights. Given the modality, particular oversight attention is placed on the specialized vendors whose outputs are decision-critical: the flow cytometry laboratory performing CD19+ B-cell enumeration (where pre-analytical sample handling and timing are critical to viable-cell measurement), the bioanalytical laboratory performing PK and ADA assays, and the central safety laboratory. Oversight combines centralized/statistical monitoring, targeted risk-based on-site and remote source data review, KRI/QTL surveillance, and periodic vendor performance review. Delegated activities remain under documented Sponsor oversight; oversight findings feed the deviation/CAPA and audit systems.
An independent, risk-prioritized audit program covers high-impact sites, critical vendors, the database and endpoint-derivation programming, safety/pharmacovigilance processes, and the TMF. The TMF is maintained inspection-ready β complete, contemporaneous, and reconciled β throughout the trial rather than reconstructed at closeout. Inspection-readiness activities anticipate Health Authority review in support of a Biologics License Application under 21 CFR Part 601, including the traceability of the primary SRI-4 and key secondary SLEDAI-2K results and the coherence of the safety narrative for the mechanism-based risks. The nonclinical and quality framework supporting the submission reflects the antibody modality: the cynomolgus monkey is the sole pharmacologically relevant toxicology species (no rodent cross-reactivity), target-mediated drug disposition informs the pharmacokinetic interpretation, and the applicable ICH guidances are Q5A(R2), Q5C, Q6B, and S6(R1); consistent with established practice for a monoclonal antibody, genotoxicity, carcinogenicity, hERG, and thorough-QT assessments are not warranted. Audit and inspection outcomes are managed through the CAPA system, with lessons learned incorporated into the evolving risk assessment and this QMP.